A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver

NCT00001587 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

NIH

Sponsor class

Conditions

Liver Neoplasms
Neoplasm Metastasis

Interventions

PROCEDURE: Isolated hepatic portal and arterial perfusion
DRUG: Melphalan

Sponsor

National Cancer Institute (NCI)